Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of SLN12140 in Healthy Volunteers
NCT06945445Phase 1Not yet recruiting
- Sponsor
- Linno Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- May 2026
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in IgA nephropathy (IgAN) comparing SLN12140 Group with Placebo Group (2 arms). Primary endpoint: Safety and tolerability of SLN12140 at 36 days. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
SLN12140
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06945445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06945445.